Extended Data Fig. 2: MitoNIDs boost the killing ability of CD8+ T cells against tumor cells.
a, Schematic diagram illustrating the experimental process of mitoNIDs enhancing CD8+ T cell toxicity. b, Images of B16-OVA tumor cells after treatment with various E:T ratios of OT-1 CD8+ T cells with or without mitoNIDs. Scale bar, 50 μm. c, LDH release in the culture supernatant. d, The degree of apoptosis of B16-OVA tumor cells detected by flow cytometry. e, Cell viability of OT-1 CD8+ T cell-treated B16-OVA tumor cells. f, Immunoblots showing cleaved caspase-3 in B16-OVA tumor cells after treatment with mitoNIDs and OT-1 CD8+ T cells. g, Images of A549 tumor cells after treatment with EGFR-CAR-T cells with or without mitoNIDs. Scale bar, 50 μm. h, The degree of apoptosis of A549 tumor cells detected by flow cytometry. i, Cell viability of EGFR-CAR-T cell-treated A549 tumor cells. j, Schematic diagram illustrating the experimental process of mitoNIDs overcoming the tolerance of tumor cells to CD8+ T cells. k, Images of B16-OVA tumor cells after treatment with OT-1 CD8+ T cells with or without mitoNIDs. Scale bar, 50 μm. l, LDH release in the culture supernatant. m, The degree of apoptosis of B16-OVA cells detected by flow cytometry. n, Cell viability of B16-OVA tumor cells. o, Immunoblots showing cleaved caspase-3 in B16-OVA cells after treatment with mitoNIDs and OT-1 CD8+ T cells. p, Microscopic images of A549 tumor cells after treatment with EGFR-CAR-T cells with or without mitoNIDs. Scale bar, 50 μm. q, The degree of apoptosis of A549 tumor cells detected by flow cytometry. r, Cell viability of EGFR-CAR-T cell-treated A549 tumor cells. All data are shown as the mean ± s.d. (n = 3 biologically independent cell samples). Two-way ANOVA with Å Ãdák’s multiple comparison was used to calculate statistical differences in c, d, e, h, i, l, m, n, q and r.
